BIRC7抗体

+ +

•  

   

     Gel: 8%SDS-PAGE, Lysate: 40 μg, Lane: Mouse adrenal gland tissue lysate, Primary antibody: P00501(BIRC7 Antibody) at dilution 1/700, Secondary antibody: Goat anti rabbit IgG at 1/5000 dilution, Exposure time: 90 seconds    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human gastric cancer tissue using P00501(BIRC7 Antibody) at dilution 1/75. (Original magnification: ×200)    

  
  

**Background of BIRC7 Antibody**

BIRC7 (Baculoviral IAP Repeat-Containing 7), also known as livin or KIAP, is a member of the inhibitor of apoptosis protein (IAP) family, characterized by a conserved baculoviral IAP repeat (BIR) domain. It functions as a key regulator of programmed cell death by inhibiting caspases, particularly caspase-3. -7. and -9. through direct binding or ubiquitin-mediated degradation. BIRC7 is notably expressed during fetal development but shows restricted expression in healthy adult tissues. However, its overexpression is frequently observed in various cancers, including melanoma, neuroblastoma, and carcinomas, where it correlates with tumor progression, therapy resistance, and poor prognosis.

Antibodies targeting BIRC7 are critical tools for studying its expression, localization, and functional roles in cancer biology. These antibodies enable detection via techniques like immunohistochemistry, Western blotting, and flow cytometry, aiding in diagnostic and prognostic assessments. Additionally, BIRC7 antibodies are explored in therapeutic strategies, such as blocking its anti-apoptotic activity to sensitize cancer cells to chemotherapy or radiation. Research also investigates isoform-specific antibodies (e.g., targeting Livinα or Livinβ splice variants) to address functional differences. Despite challenges in specificity due to structural similarities among IAPs, advancements in antibody design continue to enhance their utility in both research and clinical applications.